Life Science Nation Newsletter | September 13, 2018 | Issue 283

  The LSN Story   |   Investor Platform   |   Company Platform   |   RESI Conference   |   Fundraising Consulting
RESI NYC Early Bird Rates
Deadline Is Tomorrow 9/14

  Life Science Investor Mandates  (Sept. 6 - Sept. 12 )
Invests Broadly Across All Healthcare Sectors, with Strongest Interest in Private Biotech Companies
Seeks to Invests Up to $15M in Early-Stage Therapeutics, Medical Devices, Diagnostics, and Digital Health
Invests in Early-Stage Medical Devices, Diagnostics, and Digital Health Companies
Invests Up to $10M in Therapeutics and Medtech Companies with Strong China Market Potential
LSN Services
LSN Videos
LSN Media Partners
By Nono Hu, Director of Marketing, LSN

On September 6th, more than 700 scientist-entrepreneurs and investors entered the exhibition hall at Boston Marriott Copley Place to participate in the RESI conference. They were greeted by 30 Innovation Challenge finalists across therapeutics, medical device, diagnostics, and digital health sectors. The 30 companies, evaluated by LSN's expert system and scientific & commercial review team, competed directly on merits of innovation and commercial viability. We wish all our finalists the best in bringing their products forward toward commercialization, but there could only be 3 top prize winners.

First Prize: Heartlander Surgical

Dennis Ford, Founder & CEO, Life Science Nation | Rick Berenson, CEO, Heartlander Surgical | Dwight Meglan, CTO & Founder, Heartlander Surgical | Lucy Parkinson, VP of Investor Research, LSN

Second Prize: BrainStem Biometrics

Dennis Ford, Founder & CEO, Life Science Nation | Mike Baltay, CEO, Brainstem Biometrics | Lucy Parkinson, VP of Investor Research, LSN | Haig Armaghanian, Investor & Advisor, Brainstem Biometrics

Third Prize: PhysioCue

Dennis Ford, Founder & CEO, Life Science Nation | Jonathan Leong, CEO, PhysioCue | Lucy Parkinson, VP of Investor Research, LSN

By Lucy Parkinson, VP of Investor Research, LSN

On November 5th, RESI is coming back to New York, and will bring an agenda full of investor discussions and content on key investor constituencies and life science technology verticals. 

 RESI NYC includes new panels on AI in Healthcare and Funding NYC's Earliest Stage Companies, plus the return of the expert sessions on Investing in Oncology Innovation and Asia Cross-Border Investors. RESI will also present panels on our core technology verticals of Early Stage Therapeutics, Medical Devices, Diagnostics, and Digital Health, and on key investor types such as Angels and Family Offices, Seed Funds, Corporate Venture Capital and Big Pharma. You can view the entire agenda below. If you'd like to here from experienced investors on these key topics and book face-to-face meetings with investors all day, you can register now.

By Karen Deyo, Investor Research Analyst, LSN

The FDA is working hard to modernize the agency to adapt to the rise of digital health. In his speech on April 26th, FDA Head Scott Gottlieb noted that a clear FDA regulatory strategy for digital health is critical not only for maintaining patient safety, but to provide companies and investors a clear understanding of what, if any, regulatory requirements companies will need to meet before and after market entry. Additionally, the FDA is looking to modernize their own processes by adapting digital tools to help streamline pre-market review of therapeutic safety and for improved compliance with post-market study requirements.

When considering a digital health company for potential investment, investors will ask whether or not the tool will require any sort of FDA oversight. The FDA has determined that any digital health tool that does not have the ability to significantly impact patient safety does not require any regulation. This would include tools such as general wellness apps, tools to streamline doctor-patient communication or track patient care and records, as well as tools to ease patient access to medical records. Investors focused on technologies that don't require regulatory approval will focus on companies developing these tools when looking for digital health portfolio companies...

Created & Produced by